

INDEX

A

Abciximab, GP IIb/IIIa receptor antagonist, 107, 226

Acculink for Revascularization of Carotids in High-Risk Patients (ARCHeR) study, 242

AccuLink™ for Revascularization of Carotids in High-Risk patients (ARCHeR) trial, 41–43. *See also* Carotid artery stenting (CAS)

ACE inhibitors, 16

Activated clotting time (ACT), 165

Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial, 106

Acute ischemic stroke (IS) treatment, 215–216

cerebrovascular circulation, characteristics of, 216

endovascular approaches to, 216–218

patient selection, 218–221

interventional approach

- adjunctive pharmacotherapy, 226
- clot disruption, 226–227
- clot extraction, 227–231
- diagnostic angiography, 221–222
- occlusion site, access of, 222–224
- recanalization technique, 224–226

peri-procedural medical management, 231–234

Amaurosis fugax, 249

Amplatz Super Stiff™, 196–197

AngioGuard™ filter EPD, 48

Anterior and posterior circulation ischemia, symptoms and signs, 8

Anterior cerebral artery (ACA), 156–158

- classification, 158
- distal branches, 159

Anterior inferior cerebellar artery (AICA), 160

Anticoagulants, 16–17

Antiplatelet therapies

aspirin

and acute stroke, 11

Physician's Health Study for randomized clinical trial, 9

sex-specific meta-analysis of, 10

oral antiplatelet therapy

- recommendations for, 13

placebo-controlled and comparative studies, 12

Aortic arch

angiography, 165–166

variants, 150

Arrow Interventional Carotid Access Set, 199

Arterial access, 164–165

Arterial aneurysm, 134

Asymptomatic Carotid Atherosclerosis Study (ACAS), 24

Asymptomatic Carotid Stenosis Stenting *versus* Endarterectomy Trial (ACT-1) and (ACT-2), 59

Asymptomatic Carotid Surgery Trial (ACST), 240

collaborative study, 24

Atherothrombotic risk profile, in patients, 112

B

Basilar artery, 160

Blood Pressure Lowering Treatment

Trialists' Collaboration and ACE inhibitors, 16

Boston Scientific Carotid Wallstent® , 43

Boston Scientific EPI: A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH), 43. *See also* Carotid artery stenting (CAS)Brachial access

complications, 144

indications/contraindications, 142

methods

- Brachial access (cont.)
 hemostasis, 144
 landmarks, 143
 puncture, 143
- Brain embolization, 216
- C
- Carotid ACCULINK/ACCUNET Post-Approval Trial to Uncover Unanticipated or Rare Events (CAPTURE) registry, 243, 253
- Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS), 46, 241–242, 253. *See also* Carotid endarterectomy (CEA) Carotid artery disease screening, 118
- Carotid Artery Revascularization using the Boston Scientific EPI FilterWire EX/EZ and the EndoTex NexStent (CABERNET) trial, 43–44. *See also* Carotid artery stenting (CAS) Carotid artery stenosis
- asymptomatic
 carotid stenosis, 6
- carotid artery, surrounding nerves of, 27
- evidence-based medical therapy for, 8
 chronology of secondary prevention, 9
 primary prevention of traditional cardiovascular risk factors, 9
- extracranial carotid stenosis
 algorithm for management, 8
 relationship between anterior circulation to primary motor and sensory cortex, 8
 stroke syndromes associated with, 7–8
- lesions, 25
- prevalence of, 3–5
- risk of stroke with bypass surgery, 5
- stroke, correlation with, 5–6
- Carotid artery stenting (CAS), 37, 111, 122, 238
 American Heart Association (AHA) guidelines, 38
- anticoagulation, 172
- antiplatelet agents, before and after
 acetylsalicylic acid (ASA), 103
 heparin and aspirin, combination of, 104
 PCI-CURE and CREDO (Clopidogrel for Reduction of Events During Observation) studies, 104
 prasugrel, 104
 thienopyridines, 103
- arterial access, 172
- balloon post-dilatation, 187
- balloon pre-dilatation, 184–185
- cardiovascular hemodynamic monitoring, 263
 and carotid endarterectomy, 114–116
- and CEA trials of, 45
 ACT-1 trial, 59
 CARESS phase I clinical trial, 47–48
 Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS), 46
 CREST trials, 57–58
 EVA-3S study, 50–52
 ICSS or CAVATAS-2 study, 58–59
 meta-analyses of data, 54–55
 SPACE study, 52–54
 Stopped trial, 46
 Transatlantic Asymptomatic Carotid Intervention Trial, 59
 Wallstent study, 46–47
- complication rates, 241
 age factor and, 238–239
 symptomatic vs, asymptomatic patients, 238
- complications, prevalence of, 241–244
- contralateral carotid stenosis, 191
- diagnostic carotid and cerebral angiography, 172–175
- early large multi-center registries, 39
 European Long Term Carotid Artery Stenting Registry (ELOCAS), 40
 Global Carotid Artery Stent Registry, 40–41
 Prospective Registry of Carotid Artery Angioplasty and Stenting (Pro-CAS), 40
- emboli protection device (EPD), use of, 179
 balloon occlusion EPD, 181–183
 filter EPD, 179–181
- final carotid and cerebral angiography, 189, 190
- high surgical risk registries
 ARChER trials, 41–43
 BEACH, 43
 CABERNET trials, 43–44
 CREATE trial, 44
 MAVERIC trial, 44
 MO.MA registry, 44–45
 PASCAL study, 45
 PRIAMUS study, 45
 SECURITY trial, 45
- hyperperfusion syndrome, 264–265
- medications before
 carotid intervention, 102–103
 contrast agents use, 102
- mortality in surgical trials, 38
- neurological
 complications, 266
 examination, 98
 monitoring with, 264, 266

- post-procedural complications
 - contrast-induced nephropathy, 254, 256
 - delirium, 251–252
 - hyperperfusion syndrome, 252
 - late distal embolization, 253
 - restenosis, 253–255
 - stent deformity, 256
 - stent thrombosis, 252–253
- post-procedural monitoring, 189–190
 - management of patients, 97
- pre-discharge
 - angiotensin-converting enzyme inhibitors and statins, medications, 267
 - investigation, post-CAS carotid Doppler, 266
- procedural and early post-procedural monitoring, 262
- procedural complications
 - ischemic embolization, 245–247
 - reflex bradycardia and hypotension, 250–251
 - retinal artery embolization, 249–250
 - slow flow/no reflow/abrupt vessel closure, 247–249
 - vascular access complications, 243, 245
- randomized clinical trial (RCT), 39
 - post-market surveillance (PMS) registries of, 55–57
- reflex bradycardia, 264
- reflex hypotension, 264
- retinal cholesterol embolization, 266
- retrieval of EPD, 187–188
- routine post-procedure monitoring of carotid stent patients, 262–263
- sheath/guide approach, 175–176
 - direct guide, 179
 - guide, 178–179
 - sheath, 176–177
 - sheath *vs.* guide catheter, 177
- stent placement, 185–186
- use of anticoagulants with
 - direct thrombin inhibitors, 106
 - GP IIb/IIIa inhibitors, 107
 - low molecular weight heparins (LMWH), 105–106
 - thrombin inhibitors, 105
 - unfractionated heparin (UFH), 104–105
- Carotid endarterectomy (CEA), 21–22, 111, 113–114
 - asymptomatic carotid stenosis trials, 24–25
 - early complications
 - cranial nerve injuries, 31
 - hemorrhage and infection, 31
 - hyperperfusion and cerebral hemorrhage syndrome, 30–31
 - stroke or death, 30
 - eversion endarterectomy technique, 29–30
 - high-risk
 - criteria for, 38
 - features with, 114
 - indications for, 25–26
 - late complications
 - false aneurysms, 32
 - recurrent stenosis, 31–32
 - under local anesthesia/general anesthesia, 28–29
 - and medical management, 113
 - patch/primary closure, 29
 - patch type, 29
 - shunting, 28
 - surgical technique, 26–28
 - symptomatic carotid artery stenosis, 22–24
- Carotid intervention, 126–127
- Carotid revascularization
 - Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), 57–58, 115, 242, 243
 - Carotid Revascularization Using Endarterectomy or Stenting Systems (CARESS) phase I clinical trial, 47–48
 - Carotid Revascularization with ev3 Arterial Technology Evolution (CREATE) registry, 242
 - trial, 44
 - indications for, 117–118
- Carotid RX AccuLink™/AccuNet™ Post-Approval Trial to Uncover Unanticipated or Rare Events (CAPTURE) PMS study, 55–57
- Carotid stenting
 - contraindications to, 117
 - and physicians training, 123
 - reimbursement considerations for, 118
- Carotid Surgery *versus* Medical Therapy in Asymptomatic Carotid Stenosis (CASANOVA) trial, 24
- Carotid ultrasonography, 87
 - intraplaque hemorrhage, 89
 - right ICA
 - calcified shadowing plaque, 89
 - heterogeneous plaque, 88
 - peak systolic velocity (PSV) of, 90
 - soft homogeneous echogenic plaque, 88
 - trickle flow in, 90
 - Society of Radiologists in Ultrasound Consensus for carotid artery stenosis classification, 91
- CAS with Embolic Protection Surveillance-Post Marketing Study (CASES-PMS), 56
- Catheters
 - complex curved, 173

- Catheters (cont.)
 Simmons catheters, 173–175
 VTK catheter, 173
 simple curved, 172–173
- Cerebral angiography, 125–126
- Cerebral blood flow (CBF), 232–233
- Cerebral hemorrhage syndrome, 30–31. *See also*
 Carotid endarterectomy (CEA)
- Cerebrovascular disease, 112
 angiography, complication of, 168
- CHARISMA trial, 12
- Clinic Asymptomatic Carotid Endarterectomy
 trial, 24
- Clopidogrel drug
 Clopidogrel for High Atherothrombotic
 Risk and Ischemic Stabilization,
 Management, and Avoidance
 (CHARISMA) trial, 104
 Clopidogrel in Unstable angina to prevent
 Recurrent Events (CURE) trials, 103
 Clopidogrel *versus* Aspirin in Patients at
 Risk for Ischemic Events (CAPRIE)
 trials, 11, 103
 monotherapy for secondary prevention,
 11–12
- Cognitive knowledge
 as endorsed by AAN/AANS/ASITN/ASNR/
 CNS/SIR, 124
 as endorsed by SCAI/SVMB/SVS, 123–124
 skills and, 124–125
- Common carotid arteries (CCA), 26, 152–153
- Community trial, 47. *See also* Carotid
 endarterectomy (CEA)
- Computed tomography (CT) angiography, 77
 in acute IS, 219
 contrast injection protocols, 78
 image interpretation, 82
 image reconstruction, 78
 anatomical delineation, 81
 axial CT angiographic image, 80
 high-grade non-calcified right ICA
 stenosis, 80
 sagittal multiplanar reformat, 79
 sagittal oblique MIP image of, 81
 shaded surface display (SSD), 79
 volume rendering (VR) in, 80
 scan speed, 78
 validation studies of, 82
- Continuing medical education (CME), 128
- Contrast agents, 69. *See also* Carotid artery
 stenting (CAS)
- Contrast-enhanced magnetic resonance
 angiography (CE-MRA), 82–83
 gadolinium exposure, 86–87
 MRA validation, 87
 nephrogenic systemic fibrosis (NSF), 86
 Contrast-induced nephropathy (CIN), 254, 256
 Coronary angioplasty balloon, 184–185
 Coronary artery bypass graft (CABG), 118
 Cortical homunculus, 7
 CREATE SpiderRX arm using AccuLink™
 stent, 44
 Cristallo Ideale stent, 203
- D**
- Digital subtraction angiography (DSA), 164
- Dipyridamole, 11. *See also* Strokes
- Direct carotid access, 144
 indications/contraindications, 144
 methods
 hemostasis, 146
 landmarking and anesthesia, 144
 puncture, 145–146
 potential complications, 146
- Doppler sonography, 87–88
- E**
- Emboli protection device (EPD), 179, 200
 balloon occlusion EPD, 181, 183
 distal balloon occlusion device, 200
 proximal balloon occlusion device, 210–212
 filter EPD, 179–181
 filter EPD *vs.* guardwire® distal balloon
 occlusion EPD, 202
- Emboshield™ and Xact® Post Approval Carotid
 Stent Trial (EXACT), 57
- Emergency Management of Stroke Bridging
 Trial, 218
- Endarterectomy Versus Stenting in Patients with
 Symptomatic Severe Carotid Stenosis
 (EVA-3S) study, 50–52, 242
- European Carotid Surgery Trial (ECST),
 5–6, 23
- European Long Term Carotid Artery Stenting
 Registry (ELOCAS), 40. *See also* Carotid
 artery stenting (CAS)
- European Stroke Prevention Study
 (ESPS-2), 11
- Eversion endarterectomy technique, 29–30
- Export® catheter, 210
- External carotid artery (ECA), 26, 153–154
 bony structures
 cine angiogram of overlapping, 72
 digital subtraction angiography
 of, 73
 intimal media thickness (IMT) of, 91
 occlusion in, 92
 recommendations for imaging, 92

- Extracranial CAS, equipment for, 193–194
- angioplasty balloons
 - post-dilatation balloons, 199
 - pre-dilatation balloons, 199
 - aspiration catheters, 210
 - catheters and sheaths, selection of, 197
 - guide catheters, 198
 - sheaths, use of, 198–199
 - Type III aortic arch, diagnostic catheters for, 198
 - Types I and II aortic arch, diagnostic catheters for, 197–198
 - guidewires
 - 0.014" or 0.018" guidewires, use of, 194, 195
 - peripheral guidewires, 194, 196–197
 - stents and EMD. *See also* Emboli protection device (EPD)
 - ACCULINK™, RX-ACCULINK™ stents and ACCUNET™ EPD, 203–205
 - balloon-expandable stents, 199–200
 - closed-cell stents, 200, 203
 - emboli protection devices, 200, 201
 - Exponent® OTX, Exponent® RX, and Guardwire™ EPD, 208–210
 - Nexstent® stent and Filterwire EZ™ EPD, 208, 209
 - open-cell stents, 200, 202
 - PRECISE™ stent and Angioguard® XP EPD, 207–208
 - Protégé® GPS™, Protégé® RX stents, and SPIDER™ EPD, 206–207
 - self-expanding stents, 200, 201
 - XACT® stent and Emboshield® EPD, 204–206
- F**
- Femoral artery
- access, 135
 - complications, 139
 - indications/contraindications, 135
 - and CAS, 172
 - method for percutaneous access of CFA, 135–139
 - closure, 138–139
 - hemostasis, 138
 - landmarks, 135–136
 - puncture, 136–138
- FilterWire EX/EZ systems, 43
- Flexor® Shuttle® sheath, 198
- Fluoroscopy in angiography, 70
- bolus chase acquisition mode, 73
 - digital subtracted angiography (DSA) acquisition mode, 72
 - fluoro loop store, 71
 - roadmap fluoroscopic imaging, 74
- Foetal-type posterior cerebral artery (PCA), 163
- G**
- General Anaesthetic *versus* Local Anaesthetic for Carotid Surgery Trial (GALA), 29
- General technique for percutaneous arterial access, 134–135
- German ALKK registry, 58
- Global Carotid Artery Stent Registry, 40–41
- GooseNeck snare, 230–231
- GORE Neuro Protection System, 211–212
- Great vessel and cerebrovascular anatomy
- anterior circulation
 - anterior cerebral artery (ACA), 156–158
 - common carotid arteries (CCA), 152–153
 - external carotid artery (ECA), 153–154
 - internal carotid artery (ICA), 154–156
 - middle cerebral artery (MCA), 156
 - aortic arch, 150–152
 - and cerebrovascular angiography
 - anticoagulation, catheter preparation and contrast agents, 165
 - aortic arch angiography, 165–166
 - arterial access, 164–165
 - complications of cerebrovascular angiography, 168
 - principles of, 164
 - reverse-curve diagnostic catheters, 168
 - selective carotid angiography, 166–167
 - vertebral angiography, 167–168
 - posterior circulation
 - basilar artery, 160–152
 - Circle of Willis, 163–164
 - posterior cerebral artery (PCA), 163
 - vertebral arteries, 158–160
 - subclavian arteries, 152
- GuardWire® distal balloon occlusion protection device, 44
- Guidant AccuLink™/AccuNet™ system, 44
- H**
- Headhunter (H1) guide catheter, 198
- Heart Outcomes Prevention Evaluation (HOPE) trial, 16
- Heart Protection Study (HPS), 13
- High-osmolar contrast agents, 69. *See also* Carotid artery stenting (CAS)
- High-risk features with carotid endarterectomy, 114
- Hi-Torque Balance Middleweight Universal wire, 194, 195

- Horner's syndrome, 31, 160
Hyperperfusion syndrome, 30–31. *See also*
Carotid endarterectomy (CEA)
- I**
Imaging equipment, 68–69
In-stent restenosis (ISR), 253–254
Internal carotid artery (ICA), 26,
154–156
bifurcation of, 27
International Carotid Stenting Study (ICSS or
CAVATAS-2), 58–59
International Stroke Trial and Chinese Acute
Stroke Trial, 11
Intra-arterial thrombolysis, 217–221
thrombolytic agents, use of, 225
Intracerebral angiogram, 162
Intracranial hemorrhage (ICH), 216,
219–220
Ischemic stroke, 217
- J**
Joint Study of Extracranial Arterial
Occlusion, 23
JR4 catheter, 166
Judkin's right catheter (JR4), 197
- K**
Kaplan–Meier analysis, 24
Kentucky trial. *See* Community trial
- L**
Left common carotid artery (LCCA), 150
Left vertebral artery angiogram, 160, 161
Lipid management recommendations, 15
- M**
Magic Torque™ wire, 196
Magnetic resonance (MR) angiography, 82
arch and great vessels, stenosis, 84
coronal contrast-enhanced MRA of carotid
arteries, 84
coronal reformat of MOTSA MRA,
stenosis of left ICA, 85
2D and 3D TOF techniques, 83
3D TOFMRA of circle of Willis, 85
MATCH trial, 11–12
Mean arterial pressure (MAP), 216
Mechanical clot disruption, 226
Mechanical embolectomy, 227
Medtronic Exponent® self-expanding
stent, 44
Medtronic Interceptor Plus Carotid Filter system
with Exponent1 stent, 44
Medtronic Self-Expanding Carotid Stent
System with Distal Protection in
Treatment of Carotid Artery
Stenosis (MAVERIC) trial, 44
MERCITM clot retriever, 227–228
Microembolic signals (MES), 246
Middle cerebral artery (MCA), 156
MO.MA system, 211–212, 249
Multi-MERCITrial, 229
- N**
National Council on Radiation Protection and
Measurement (NCRPM), recommended
exposure, 74
National Institute of Health Stroke Scale (NIHSS)
score, 98, 218–219
Neurovascular coalition (NVC), 122
guidelines, 126
NIH Stroke Scale, 98
scoring system, 99–101
Nitinol stents. *See* Stents
North American Symptomatic Carotid
Endarterectomy Trial (NASCET) study,
5, 23, 113, 240
Northern Manhattan Stroke Study, 5
- O**
OTW SpiderFX filter protection system for CAS in
high-risk patients, 44
- P**
Palmaz® stent, 256
PCI-CURE and CREDO (Clopidogrel for
Reduction of Events During Observation)
studies, 104
Penumbra™ system, 229–230
Percutaneous® GuardWire™, 200
Performance and Safety of Medtronic AVE
Self-Expandable Stent in Treatment
of Carotid Artery Lesions (PASCAL)
study, 45
Perindopril Protection Against Recurrent Stroke
Study (PROGRESS), 16
Peripheral guidewires, used in CAS, 194
flexible peripheral wires, 194, 196
hydrophilic wires, 196
stiff guidewires, 196–197
Pinnacle® Destination® sheath, 198
Plaque morphology, 91–92
Platelet GP IIb/IIIa receptor antagonists use, in
acute IS, 226, 227
Posterior cerebral arteries (PCA), 160, 163
Precise™ nitinol self-expanding
stent, 48

- Prevention Regimen for Effectively avoiding Second Strokes (PROFESS) trial, 12
- Prolyse in Acute Cerebral Thromboembolism II (PROACT II) trial, 217, 223, 225–227
- Pronto™ V3 device, 210
- Prospective Registry of Carotid Artery Angioplasty and Stenting (Pro-CAS), 40. *See also* Carotid artery stenting (CAS)PROspective Study of Pravastatin in Elderly at Risk (PROSPER) trial, 14
- Protégé stent/SpiderFX EPD system, 44
- Proximal balloon occlusion EPD design, 210–212
- Proximal Flow Blockage Cerebral Protection during Carotid Stenting (PRIAMUS) study, 45
- Pseudoaneurysm, 134
- R**
- Radial access, 139
indications/contraindications, 139–140
methods
 complications, 142
 hemostasis, 141–142
 landmarks, 140
 puncture, 140–141
- Radiation safety of patients
 2004 ACCF/AHA/HRS/SCAI clinical competency statement for, 74
 as low as reasonably achievable (ALARA) concept, 74
- Recombinant tissue plasminogen activator (rt-PA), and acute IS, 217, 225
- Reduction of Atherothrombosis for Continued Health (REACH) Registry, 5, 112
- Registry Study to Evaluate Emboshield™ Bare Wire Cerebral Protection System and Xact® Stent in Patients at High Risk for Carotid Endarterectomy (SECURITY) trial, 45
- Retroperitoneal bleeding, 134
- Right common carotid artery (RCCA), 151
- RX AccuLink™/AccuNet™ EPD system, 55–57
- S**
- SCAI/SVMB/SVS guidelines, 125
- Seldinger technique, 134, 172
- Selective carotid angiography, 166–167
- Simmons catheters, reforming techniques
 aortic valve method, 175
 left subclavian artery technique, 175
 scissoring technique, 174
- Simulation role, 128
- Smart™ nitinol self-expanding stent, 48
- SpiderRX device, 44
- Statin treatment, 13
 trials for, 14
- Stents
 for ostial/proximal ICA lesion, 185–186
 self-expanding nitinol/steel stents, 185, 200
- Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial, 48, 242, 253
 MAE rate, 49–50
- Stent-Supported Percutaneous Angioplasty of Carotid Artery *versus* Endarterectomy (SPACE) study, 52
 clinical endpoints, 54
 30-day outcomes after treatment in, 53
 study design and power, 53
 technical issues, 53–54
- Streptokinase, 225
- Strokes
 asymptomatic carotid artery stenosis severity and annual ipsilateral stroke risk, 6
 dipyridamole, 11
 incidence, 5
 ischemic stroke
 secondary prevention measures for, 9
 secondary stroke prevention, 14–15
 incidence of recurrent stroke in patients without CAD, 15
- Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, 14
- syndromes associated with extracranial carotid stenosis, 7–8
- systolic and diastolic hypertension, 16
- thromboembolic, 4
- transient ischemic attack (TIA), 22
- Subclavian arteries, 152
- Super Arrow-Flex® sheath, 199
- Superior Yield of the New strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial, 105
- Symptomatic Severe Carotid Stenosis (EVA-3S), 115
- T**
- Telescoping technique, 178
- Thrombectomy, 229
- Thromboxane A2, 103
- Transatlantic Asymptomatic Carotid Intervention Trial, 59
- Transient ischemic attack (TIA), 112, 241, 243
- Treating to New Targets (TNT) trial, 14
- V**
- Vascular interventional surgical trainer (VIST) simulator, 128
- Vertebral angiography, 167–168

Vertebral arteries, 158–160
Veterans Affairs Asymptomatic Trial (VAAT), 24
Veterans Affairs Symptomatic Trial (VAST), 23–24
Von Willebrand factor, 9. *See also* Carotid artery stenosis
VTK catheter, 168, 173, 178, 198

W

Wallstent[®], 47–48, 200
Wallstent study, 46–47. *See also*
Carotid endarterectomy (CEA)

Warfarin secondary prevention therapy,
16–17
Wholey Hi-Torque Floppy wire,
194, 196
Women's Health Study, 9–10
statins, 13

X

X-Ray system
with digital flat-panel technology, 71
image intensifier, 70